Portal de investigación
Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+solid tumors in HLA-A*02:01+patients
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Vrohlings, Melissa
- Morotti, Matteo
- Lenherr-Frey, Daniel
- Vachtsevanou, Nikolina
- Price, Clare
- Borras, Leonardo
- Bingel-Erlenmeyer, Rouven
- Swiecicki, Paul
- Olazagasti, Coral
- Leidner, Rom
- Diamond, Mark
- Rohrberg, Kristoffer
- Rottey, Sylvie
- Prenen, Hans
- Machiels, Jean-Pascal
- Kotecki, Nuria
- Calvo, Alberto Hernando
- de Velasco, Guillermo
- Perez, Desamparados Roda
- Martin Liberal, Juan Jesus.
- Simonelli, Matteo
- Curigliano, Giuseppe
- Leisner, Christian
- Biswas, Swethajit
- Aller, Emiliano Calvo
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 1535-7163, 1538-8514
- Tipo:
- Meeting Abstract
- Páginas:
- -
- Factor de Impacto:
- 1,831 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
MOLECULAR CANCER THERAPEUTICS AMER ASSOC CANCER RESEARCH
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Cita
Vrohlings,M,Morotti,M,Lenherr,D,Vachtsevanou,N,Price,C,Borras,L,Bingel,R et al. Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+solid tumors in HLA-A*02:01+patients. 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404:AMER ASSOC CANCER RESEARCH. 2025.